Document Detail

Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells.
MedLine Citation:
PMID:  21030039     Owner:  NLM     Status:  MEDLINE    
PURPOSE: We evaluated the antitumor effects of docetaxel (Sigma®) and histone deacetylase inhibitors in hormone refractory prostate cancer cells, and analyzed the mechanism by which combination treatment induced cell death.
MATERIALS AND METHODS: We used LNCaP, DU145 and PC3 cells (ATCC®) to evaluate the in vitro apoptotic effects of histone deacetylase inhibitors and their combinations with docetaxel as well as the molecular mechanisms. The DU145 xenograft model was used to evaluate the in vivo efficacy of PXD101 combined with docetaxel.
RESULTS: Suberoylanilide hydroxamic acid or PXD101 inhibited the growth of hormone dependent LNCaP cells, and hormone independent DU145 and PC3 cells. It increased sub-G1 population and activated caspase-8, 9 and 3, indicating apoptosis induction. Pretreating DU145 cells with docetaxel followed by histone deacetylase inhibitors showed significant synergistic cytotoxicity compared with that of simultaneous co-treatment or reverse sequential treatment. Pretreatment with docetaxel followed by histone deacetylase inhibitors increased the apoptotic sub-G1 population, caspase activation and tubulin acetylation compared with that of docetaxel alone. Combination treatment decreased Mcl-1 and Bcl-xl, and increased t-Bid, Bik and Bim. Combined docetaxel and PXD101 reduced tumor size with efficacy equivalent to that of a double dose of docetaxel alone in the DU145 xenograft model.
CONCLUSIONS: These preclinical results indicate that the sequential combination of docetaxel and histone deacetylase inhibitors led to a synergistic increase in the death of hormone refractory prostate cancer cells via intrinsic and extrinsic apoptotic pathways by modulating Bcl-2 family proteins and tubulin in vitro and in vivo. Results suggest that this combination may be a new therapeutic modality in patients with hormone refractory prostate cancer.
Jung Jin Hwang; Yong Sook Kim; Mi Joung Kim; Dong Eun Kim; In Gab Jeong; Choung-Soo Kim
Related Documents :
8100859 - The neuroendocrine cell population of the human prostate gland.
19891779 - A selective eradication of human nonhereditary breast cancer cells by phenanthridine-de...
9927759 - A new signal sequence trap using alkaline phosphatase as a reporter.
16267859 - Aurora b expression directly correlates with prostate cancer malignancy and influence p...
16822939 - Prostasin regulates epithelial monolayer function: cell-specific gpld1-mediated secreti...
10419589 - Oestrogen receptor expression in the normal and pre-cancerous breast.
9108389 - P53 is not required for regulation of apoptosis or radioprotection by interleukin-3.
14748539 - Small heat shock protein hsp27 as a possible mediator of intercellular adhesion-induced...
1663879 - Methimazole increases thyroid-specific mrna concentration in human thyroid cells and fr...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-10-28
Journal Detail:
Title:  The Journal of urology     Volume:  184     ISSN:  1527-3792     ISO Abbreviation:  J. Urol.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-12     Completed Date:  2010-12-30     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  0376374     Medline TA:  J Urol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2557-64     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Institute for Innovative Cancer Research, Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Apoptosis / drug effects
Drug Synergism
Histone Deacetylase Inhibitors / pharmacology*,  therapeutic use*
Mice, Inbred BALB C
Prostatic Neoplasms / drug therapy*
Proto-Oncogene Proteins c-bcl-2 / drug effects*
Taxoids / therapeutic use*
Tubulin / drug effects*
Tumor Cells, Cultured
Reg. No./Substance:
0/Histone Deacetylase Inhibitors; 0/Proto-Oncogene Proteins c-bcl-2; 0/Taxoids; 0/Tubulin; 15H5577CQD/docetaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Serologically defined human metapneumovirus in pediatric community-acquired pneumonia.
Next Document:  Receptor mediated agglutination of human spermatozoa by spermagglutinating factor isolated from Stap...